Related Experiment Videos
Combining bisphosphonates with hormone therapy for postmenopausal osteoporosis
Margaret E Fadanelli1, Henry G Bone
1St. John Hospital and Medical Center, Detroit, Michigan, USA.
Treatments in Endocrinology
|October 30, 2004
Summary
Combining osteoporosis medications like bisphosphonates with hormone therapy or raloxifene shows greater bone mineral density increases than single treatments. Combination therapy is generally well-tolerated but not needed for most patients.
Area of Science:
- Endocrinology
- Bone Metabolism
- Geriatric Medicine
Background:
- Osteoporosis is a significant postmenopausal health issue, leading to fragility fractures and morbidity.
- Current therapies (estrogens, SERMs, bisphosphonates, calcitonin) inhibit bone resorption.
- Combination therapies are being investigated for enhanced efficacy over monotherapy.
Purpose of the Study:
- To review prospective randomized clinical trials on combination therapies for postmenopausal osteoporosis.
- To compare the effectiveness of combined hormone therapy or raloxifene with bisphosphonates against single-agent treatments.
Main Methods:
- Review of eight prospective randomized clinical trials of hormone therapy combined with bisphosphonates (etidronate, alendronate, risedronate).
- Inclusion of one study combining a selective estrogen receptor modulator (raloxifene) with alendronate.
- Primary endpoint: Bone mineral density (BMD) change at the lumbar spine; secondary endpoints: femur BMD.
Main Results:
- All studies showed greater BMD increases with combination therapies versus single agents.
- Bone turnover markers were more suppressed in combination groups, remaining within premenopausal ranges.
- Bone histomorphometry data from four studies indicated no impairment of bone quality.
Conclusions:
- Combination therapies, particularly bisphosphonates with hormone therapy, may benefit women with persistent bone loss or menopausal symptoms.
- The added benefit of raloxifene with bisphosphonates is smaller but potentially useful for breast cancer risk reduction.
- Combination treatments were well-tolerated, with no significant difference in discontinuation rates.